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INTRODUCTION
Vascular endothelial growth factor (VEGF) is the most widely 
studied angiogenic factor, being considered crucial for tumor 
angiogenesis [1]. VEGF presents itself as a signal protein that 
stimulates the growth of new blood vessels and it is thought to 
facilitate the metastatic spread of tumor cells [1,2]. The pathway 
for signal transduction of VEGF is composed of 5 glycoproteins 
belonging to the VEGF family including VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and placental growth factor, 3 receptors; VEGF 
receptor-1 (FTL-1), VEGF-R2 (FLK-1/KDR), and VEGF-R3 (FLT-
4), and 2 coreceptors (NRP-1, NRP-2) [2]. The three VEGF-Rs 
participate differently in angiogenesis and lymphangiogenenis: 
VEGF-R1 and VEGF-R2 mediate angiogenesis, and VEGF-R3 is 
mostly involved in lymphangiogenesis [2]. The main inducers 
of new lymphatic vessels are the principal ligands of VEGF-R3 
[2]. In addition to the role in tumor growth, it appears that 
VEGF also has autocrine functions, acting as a survival factor 
for tumor cells, protecting them from stresses such as hypoxia, 
chemotherapy (CT) and radiotherapy (RT) [3]. Exogenous VEGF 
could attenuate the effect of RT, so combining RT with VEGF 
inhibitor could be more effective than RT alone [4,5]. A recent 
review that explores the benefit of adding target therapy to 
neoadjuvant chemotherapy in locally advanced rectal cancer 
leaves several open questions in conclusion, such as that patient 
selection should be based on potential predictive biomarkers 
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Purpose: Despite plasma biomarkers offering a number of advantages over tissue-based markers, the relationship 
between serum vascular endothelial growth factor (VEGF) and VEGF receptor (VEGF-R) tumor expression in colorectal 
cancer (CRC) is still unclear. This study was designed to establish the relationship between the concentration of serum 
VEGF and tumor VEGF-R expression in patients with CRC.
Methods: A prospective study of consecutive patients undergoing elective colorectal surgery during 1 year. Preoperative 
VEGF was determined by enzyme-linked immunosorbent assay and VEGF-R3 by immunochemistry.
Results: The initial sample included 134 patients with CRC diagnosis. Results showed significant association of serum 
values of VEGF with VEGF-R3 expression (P < 0.001), even in the presence of confounders (sex, age, body mass index, 
tumor location, and surgical approach). The estimated effect size was high (η2 = 0.35).
Conclusion: Serum VEGF has a significant correlation with tumoral VEGF-R3 expression in CRC.
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Key Words:  Colorectal neoplasms, Vascular endothelial growth factors, Enzyme-linked immunosorbent assay, 
Immunohistochemistry
16
Annals of Surgical Treatment and Research 2019;97(1):15-20
of response, such as free VEGF, in order to define a subgroup 
of patients who are more likely to benefit from this form of 
therapy [6]. 
VEGF can be measured in the tumor tissue by immuno-
histochemistry or reverse transcription polymerase chain 
reaction or in the plasma by enzyme-linked immunosorbent 
assay (ELISA) method [7]. Detection of serum VEGF has 
been investigated as a potential serum diagnostic marker for 
malignant disease, and was found to increase concentrations 
of free VEGF in various types of cancer, including those of 
gastrointestinal etiology [8,9]. However, the relationship 
between the pattern of production of VEGF protein in tumor 
tissues and its concentration in the circulation remains unclear 
[10,11]. 
Plasma biomarkers offer a number of advantages over tissue-
based markers. The potential of serum concentration of VEGF 
being representative of tumor VEGF opens new pathways for 
further investigation, preoperative prognostic information and 
treatment response. The absence of papers designed to verify 
this relationship lead us to design a study with the intention of 
clarifying the relationship between the concentration of serum 
VEGF and tumor VEGF-R expression in patients with CRC.
METHODS
Study oversight and patient inclusion 
Between August 2015 and August 2016 all patients with 
a confirmed diagnosis of colorectal adenocarcinoma who 
underwent elective surgery at our institution were enrolled. 
Patients who presented evidence of metastasis before or at 
surgery, necessity of removal of other organs due to tumor 
invasion, synchronous tumors or history of other malignant 
tumors within 5 years, history of familial adenomatous 
polyposis and hereditary nonpolyposis colorectal carcinoma 
were excluded. We also excluded patients who did not do 
preoperative assessment, did not have preoperative blood 
samples collected, malignant polyp excised but without tumor 
in the colectomy specimen, pathologic completed response 
after neoadjuvant CT – ypT0, or adenocarcinoma in situ and 
mucinous adenocarcinoma. 
Written informed consent was obtained from all participant 
patients. This study was approved by the Ethics Committee for 
Health of Hospital de Braga (authorization number 60/2017). 
Data collection 
At 1 day before surgery, the same nurse performed an 
anthropometric evaluation of the patients that included body 
weight and height and obtained a sample for the evaluation of 
serum VEGF. A biopsy representative of each tumor was taken 
from Department of Pathology.
Immunohistochemistry
One representative histological specimen of each case at the 
deepest invaded area of the CRC lesion was selected by same 
pathologist for immunohistochemistry. Immunohistochemical 
staining was performed on the samples with a thickness of 
2.5 µm, which were cut using the Thermo – MicroM HM355S 
with a simultaneous water bath at 56℃ for flattening out and 
drying tissue sections (Medite TFB45). After the water bath, 
the cut samples were placed on specific slides for a period 
of 20 minutes at 60℃ in the Memmert Model 100–800. For 
the removal of paraffin, BondTM Dewax Solution (Catalog 
number AR9222, Leica Biosystems, Wetzlar, Germany) was 
used followed by VEGF-R protocol for Mouse Monoclonal 
Antibody VEGFR-3 (dilution 1:50; clone KLT9; Product code 
NCL-L-VEGFR-3, Leica Biosystems). The antibody was diluted 
with Novocastra TM IHC Diluent (Product Code RE7133, Leica 
Biosystems). All sections were incubated with primary antibody 
incubation for 60 minutes at 25℃. Staining was performed 
using the BOND - MAX Automated from Leica following the 
manufacturer’s procedures. It was used with the following 
products: BondTM Wash Solution 10X Concentrate (Catolog 
number AR9590, Leica Biosystems), BondTM Epitope Retrival 
solution 1 (Catolog number AR 9961, Leica Biosystems) and 
BondTM Polymer Refine Detection (Catolog number DS9800, 
Leica Biosystems).
Then the slides were washed in distilled water. Afterwards, 
the slides were dehydrated in an ascending series of alcohols 
(70%, 96%, and 100%) and made diaphanous with xylene, and 
finally mounted with Entellan glue. 
Microscopic assessment of VEGF-R3 expression
VEGF-R3 staining was graded according to the intensity 
and extent of staining of the endothelium of the vessels as 
previously published [12]. The scale presenting hence is the 
following: 0 = absent (Fig. 1A), 1 = weak/very limited moderate 
staining (Fig. 1B), 2 = moderate widespread/strong localized 
staining (Fig. 1C) and 3 = strong widespread (Fig. 1D). This 
was assessed under ×100 magnification for all of the sections 
taken. 
Serum VEGF determination 
For determination of serum VEGF levels, blood samples were 
collected from the day before surgery. Serum samples were 
obtained by centrifugation at 3,000 revolutions per minute for 
10 minutes and were stored at -80ºC until use. Serum levels 
of VEGF were determined using a commercially available 
sandwich enzyme immunoassay kit (Human VEGF ELISA 
kit; Catalog number KHG0111, KHG0112, Life Technologies, 
Carlsbad, CA, USA). Samples were prepared and tested in 
duplicate according to the manufacturer’s instructions. The 
reported detection limit is <5 pg/mL.
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Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 
ver. 24.0 (IBM Co., Armonk, NY, USA). Descriptive statistics 
were presented as means (M) and standard deviations (SD) 
for quantitative variables; categorical variables we computed 
frequencies (n) and percentages (%). Normality was checked 
with Shapiro-Wilks test assuming normality for P > 0.05. 
Levene test was used for assessing the homogeneity of 
variances, making this assumption when P > 0.05. One-way 
analyses of variance (ANOVA) was used to compare serum 
values of VEGF. Spearman correlation was used to measure 
the association between these variables. Confounders were 
controlled by conducting an analyses of covariance (ANCOVA). 
Effect size was measured with eta2 (η2), considering low effect (η2 
= 0.01), moderate effect (η2 = 0.06) and high effect (η2 = 0.14). 
Significant results were considered for P < 0.05.
RESULTS
Study population and baseline characteristics
The initial sample included 134 patients with CRC diagnoses. 
From these, 60 patients (44.8%) were excluded for the following 
reasons: no preoperative assessment (26; 19.4%), lack of 
preoperative blood samples (19; 14.2%), pathologic completed 
response after neoadjuvant CT – ypT0 (5; 3.7%), malignant polyp 
excised but without tumor in the colectomy specimen (4; 3.0%), 
adenocarcinoma in situ (4; 3.0%), mucinous adenocarcinoma 
(1; 0.7%), and lack of sample (1; 0.7%). The final sample was 
composed of a total of 74 patients with CRC diagnoses, 47 
Fig. 1. Immunohistochemical 
staining for VEGF-R3 in malignant 
colorectal endothelium. (A) 
Absent expression of VEGF-R3 
in CRC (×100). (B) Weak/very 
limited moderate staining of 
VEGF-R3 (×100). (C) Moderate 
widespread/strong localized 
staining of VEGF-R3 (×100). (D) 
Strong widespread staining of 
VEGF-R3 (×100). VEGF, vascular 
endo thelial growth factor; VEGF- 
R3, VEGF receptor 3; CRC, color-
ec tal cancer. 
Table 1. Patient and tumor characteristics
Characteristic Value
Age (yr) 68.34 ± 12.69
Sex
    Male 47 (63.5)
    Female 27 (36.5)
Location
    Rectum 18 (24.3)
    Colon 56 (75.7)
Surgical approach
    Laparotomy 38 (51.4)
    Laparoscopy 33 (44.6)
    Conversion from laparoscopy 3 (4.1)
Body mass index (kg/m2) 26.97 ± 4.08
T classification (TNM)
    T1 5 (6.8)
    T2 21 (28.4)
    T3 44 (59.5)
    T4 4 (5.4)
N classification (TNM)
    N0 51 (68.9)
    N+ 23 (31.1)
Dukes stage
    Dukes A 20 (27.0)
    Dukes B 31 (41.9)
    Dukes C 23 (31.1)
Values are presented as mean ± standard deviation or number 
(%).
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males (63.5%) and 27 females (36.5%) with a mean age of 68 
years. Other patient and pathologic characteristics are described 
in Table 1.
Analytic results
After checking for normality and variances homogeneity, 
ANOVA results showed overall significant differences (P < 0.01, 
η2 = 0.34). Tukey multiple comparisons test showed significant 
differences regarding the comparison of strong widespread 
staining (mean ± SD, 126.39 ± 77.31) with all other categories: 
moderated widespread/strong localized (mean ± SD, 65.35 ± 
36.21), weak/very limited moderated (mean ± SD, 49.68 ± 
18.96), and absent (mean ± SD, 36.29 ± 12.55) (Table 2, Fig. 2). 
Spearman correlation showed significant association between 
these variables (ρ = 0.348, P = 0.002).
An ANCOVA analysis intending to control for the confounders: 
age, sex, body mass index, tumor location, surgical approach, 
TNM, and Dukes classification was performed. Results showed 
significant association of serum values of VEGF with VEGF-R3 
expression (P < 0.01), even in the presence of all referred 
confounders. Effect size estimate was η2 = 0.35 (Table 3).
DISCUSSION
The relationship between VEFG and CRC outcomes is 
controversial. Some studies showed that VEGF has no 
significant prognostic value in CRC [13], but many others have 
demonstrated an association between overexpression of VEGF 
and poor CRC outcomes: the overexpression of VEGF and 
VEGF-R in CRC tissue indicates poor prognosis [4,14,15], predicts 
early relapse [16], and preoperative VEGF serum concentration 
predicts poor disease-specific survival and disease-free 
survival in colon cancer patients [17]. When comparing 
patients who had metastatic tumors compared with patients 
who had nonmetastatic tumors, it was found that VEGF 
expression was higher in the first group [18-20]. Takahashi et 
al. [21] demonstrated that VEGF expression levels in patients 
with lymph node negative CRC was significantly associated 
with time to recurrence, and Cascinu et al. [22] verified the 
association between positive VEGF tumor status with a 
significant reduction in the 5-year disease-free survival rate. 
Some studies have shown that VEGF is also a useful prognostic 
marker, by significantly correlating with angio-lymphatic 
invasion, lymph node status, and depth of invasion, although it 
is not an independent prognostic factor [10]. 
Regardless of serum VEGF collected before the surgery 
theoretically presenting many advantages over tumoral VEGF, 
Table 2. ANOVA comparison for serum VEGF and tumoral VEGF-R3 expression






localized (n = 13)
Strong widespread 
(n = 6) ANOVA
Serum VEGF concentration 36.29 ± 12.55 49.68 ± 18.96 65.35 ± 36.21 126.39 ± 77.31 P < 0.001
η2 = 0.34
Values are presented as mean ± standard deviation.
ANOVA, analysis of variance; VEGF, vascular endothelial growth factor; VEGF-R3, VEGF receptor 3.
Fig. 2. Serum values of VEGF distribution by immuno-
chemistry VEGF-R3 expression. VEGF, vascular endothelial 
growth factor; VEGF-R3, VEGF receptor 3; CRC, colorectal 
cancer. 
Table 3. ANCOVA analysis of covariance for serum values 
of VEGF by VEGF-R3 expression adjusted for age, sex, body 
mass index, location, surgical approach, T classification, N 
classification, and Dukes classification
Variable P-value η2
VEGF-R3 expression <0.001 0.35
Age 0.315 0.02
Sex 0.197 0.03
Body mass index 0.280 0.02
Location 0.747 0.02
Surgical approach 0.809 0.01
T classification (TNM) 0.218 0.02
N classification (TNM) 0.260 0.02
Dukes classification 0.185 0.03
ANCOVA, analysis of covariance; VEGF, vascular endothelial 
growth factor; VEGF-R3, VEGF receptor 3.
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only a few studies evaluated the prognostic impact of VEGF 
serum levels in patients with CRC. The Danish Colorectal 
Cancer Study Group conducted a large study which suggested 
a biologically relevant role for serum VEGF concentrations in 
patients with CRC, after having found that high preoperative 
VEGF concentrations were associated with a reduced overall 
survival [23-25]. In the same way, Nakayama et al. [26] reported 
on elevated circulating levels of VEGF in patients with CRC who 
had more advanced disease and in patients who experienced 
tumor recurrence. 
Probably one of the reasons for serum VEGF being used 
as prognostic marker in only a few papers is related to the 
absence of studies designed with the purpose of clarifying 
the relationship between serum and tumoral VEGF. Our work 
showed a strong association (P < 0.001, η2 = 0.34) between 
preoperative serum VEGF and VEGF-R3 tumor expression even 
after controlling for potential confounders. This association 
could be explained by previous studies that show that VEGF 
is expressed in a wide variety of human tissues, particularly 
high quantity in tumors, and that, in vitro, many tumor cell 
lines secrete VEGF [17]. Thus, it seems logical that patients with 
tumor cells with a higher expression of VEGF-R present higher 
levels of serum VEGF in comparison with tumors with lesser 
VEGF-R expression.
These results open up new horizons in terms of investigation 
as a potential biomarker in selection of treatment and prog-
nostic information. In the near future, it may be possible to 
implement a patient selection strategy to effectively identify 
those patients who are most likely to benefit from neoadjuvant 
treatment with VEGF inhibitors based on this confirmed 
relationship between serum and tumoral VEGF expression. 
However, due to limitation of sample size, our work needs to 
be considered as a pilot study. Further studies with a larger 
sample need to be developed in order to confirm these results. 
Moreover, our study only focuses on the relationship between 
serum VEGF and tumor VEGF-R expression, so the prognostic 
significance of serum VEGF still requires further investigation.
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